drugset / Trial / NCT04661709

Summary

This is a double-blind, randomized placebo-controlled trial which aims to evaluate the efficacy and safety of Wen Xin granule in patients with unstable angina pectoris.

Timeline

Start
2021-03-01
Primary completion
2023-03-01
Completion
2023-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Wen Xin granule Unknown Oral
Background Aspirin Small molecule 100 mg Oral
Background Atorvastatin Small molecule 20 mg Oral
Background Clopidogrel Small molecule 75 mg Oral
Background Isosorbide Mononitrate Other / unclassified 20 mg Oral
Background Metoprolol Other / unclassified 12.5 mg Oral
Background Metoprolol Other / unclassified 25 mg Oral
Background Nitroglycerin Unknown
Background Trimetazidine Small molecule 20 mg Oral